Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex (NYSE: TFX) will host a conference call on May 4, 2023, at 8:00 a.m. ET to discuss its first quarter financial results and operational updates. Participants can pre-register using the provided link to receive dial-in information. The call will be available via audio webcast on the Teleflex website, and a replay will be accessible after 11:00 a.m. ET on the same day. Teleflex is a global leader in medical technologies aimed at enhancing health and quality of life, with a diverse portfolio in areas such as vascular access, anesthesia, and surgical solutions. For further information, stakeholders can visit Teleflex's official website.
Teleflex Incorporated (NYSE: TFX) has announced a supply agreement with W. L. Gore & Associates to integrate GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement into its Titan SGS® Powered Stapling Device for bariatric surgery. This partnership aims to enhance surgical outcomes by combining the advanced technology of the Titan device, specifically designed for sleeve gastrectomy, with Gore's proven staple line reinforcement material. The Titan SGS® offers significant advantages, including reducing stapling time by half and providing a consistent gastric sleeve anatomy. The collaboration highlights both companies' commitment to innovation in the bariatric surgery space.
Teleflex (NYSE: TFX) presented significant findings regarding the UroLift® System for treating benign prostatic hyperplasia (BPH) at the 38th Annual European Association of Urology Congress. Research from over 330 controlled subjects indicates that the UroLift® offers durable results at one and five years, with lower durability linked to undertreatment. Early intervention positively affects quality of life and sexual function. Notably, UroLift® demonstrated a lower complication rate compared to traditional surgeries like TURP. The studies reinforce UroLift® as a leading minimally invasive treatment for BPH, emphasizing its safety and effectiveness.
Teleflex is set to present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, at 12:00 p.m. (ET). Thomas Powell, the Executive Vice President and Chief Financial Officer, will deliver the presentation. A live audio webcast will be accessible on the Teleflex investor website. Teleflex, traded as TFX on NYSE, specializes in medical technologies aimed at enhancing health and quality of life, offering solutions across various fields including vascular access, anesthesia, and surgical care. For more details, visit teleflex.com.
Teleflex (NYSE: TFX) has announced a quarterly cash dividend of $0.34 per share, payable on March 15, 2023. Shareholders of record as of March 3, 2023 will receive this dividend. Teleflex is dedicated to delivering innovative medical technologies aimed at enhancing healthcare quality and outcomes. Their product range spans multiple sectors, including vascular access, interventional cardiology, and anesthesia. This dividend declaration reflects the company's commitment to returning value to its shareholders while supporting ongoing business growth.
Teleflex Incorporated (NYSE: TFX) reported its Q4 2022 financial results, with revenues of $758.0 million, a slight decline of 0.5% year-over-year, but a 3.7% rise on a constant currency basis. GAAP diluted EPS decreased to $1.65 from $2.69 in Q4 2021. For full year 2022, revenues were $2,791.0 million, down 0.7%, with a GAAP diluted EPS of $7.67, compared to $10.23 in 2021. Looking ahead, Teleflex expects revenue growth of 4.25% to 5.75% for 2023, and GAAP EPS guidance of $8.26 to $8.86. The company emphasizes its commitment to durable growth amidst challenges.
Teleflex Incorporated (NYSE: TFX) announced significant advancements in interventional cardiology with the FDA 510(k) clearance of the Triumph™ Catheter and the first clinical use of the GuideLiner® Coast™ Catheter. The Triumph™ Catheter features six wire exit ports designed for better navigation in complex anatomy. Developed with Dr. Bill Nicholson, it aims to improve catheter navigation. The GuideLiner® Coast™ Catheter adds hydrophilic options to the existing portfolio. Both products will be showcased at the CTO Plus Conference on February 23-24 in New York, with full market release expected later in 2023.
Teleflex Incorporated (NYSE: TFX) will have its Chairman, President, and CEO, Liam Kelly, speaking at the 44th Annual Raymond James Institutional Investors Conference on March 7, 2023, at 1:40 p.m. (ET). The conference will take place at the JW Marriott Orlando Grande Lakes, Orlando, FL.
A live audio webcast and accompanying presentation slides will be available on the investor section of Teleflex's website for those unable to attend in person.
Teleflex specializes in innovative medical technologies that improve healthcare quality, offering solutions across various medical fields.
Teleflex Incorporated (NYSE: TFX) will hold a conference call on February 23, 2023, at 8:00 AM ET to discuss its fourth-quarter financial results and provide an operational update. Interested participants can pre-register for the call through a provided link or access it via a live audio webcast on the company’s website. A replay of the call will be available later that day. Teleflex is a leading global provider of medical technologies, focusing on innovative solutions across various healthcare sectors including vascular access, anesthesia, and emergency medicine. For more details, visit their official website.
Teleflex (NYSE: TFX) announced a new agreement with Premier®, Inc. for its Titan SGS® powered stapling device, designed for sleeve gastrectomy procedures. This collaboration enables Premier members to access competitive pricing on the Titan SGS®, which is uniquely indicated for gastric pouch creation. The device has proven to cut staple time in half and facilitates consistent gastric anatomy, boasting a 23cm staple line. Over 6,000 procedures have utilized the Titan SGS® since its 2021 launch. Teleflex's partnership with Premier is expected to enhance the distribution of this advanced surgical technology nationwide.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
